Nasal Spray May Eliminate SARS-CoV-2 Virus
A new in vitro study by Utah State University and Northwestern University finds Xlear components (grapefruit seed extract and xylitol) significantly eliminates SARS-CoV-2, the coronavirus that causes COVID-19.
The non-peer-reviewed study published on December 21, 2020, tested SARS-CoV-2 virus titers and LRV against a single concentration of Xlear nasal spray.
According to the study’s findings, “After a 25-minute contact time, the nasal spray reduced virus from 4.2 to 1.7 log10 CCID50 per 0.1 mL, a statistically significant reduction (P<0.001) of 2.5 log10 CCID50.” The potential in saving lives and the economies of the world by using X-GSE combination therapy should inspire large clinical trials
The Northwestern - Utah State Study is the newest in a string of studies to conclude that Xlear is effective against the SARS-CoV-2.
However, this study breaks new ground in two vital respects.
“First, we conclude, in addition to countering SARS-CoV-2, Xlear is likely effective in preventing the spread of future H1N1 viruses, including the emerging SARS-CoV-2 variants, along with other viral epidemics. Given the more transmissible variants we now face, this is critical now,” said Professor Mark Cannon, Feinberg School of Medicine, Northwestern University, in a press release issued on January 26, 2021.
“Second, using electron microscopy, we have visual evidence showing that xylitol and GSE counter the virus. The grapefruit seed extract (GSE) kills the virus, while the xylitol prevents the virus from attaching to the cell walls.”
“The image shows SARS-CoV-2 viruses outside the cell and never attached, thereby preventing infection,” added Dr. Cannon.
The study postulates that xylitol acts as a decoy target for SARS-CoV-2, preventing virus attachment to the cell wall’s core protein.
The collaborative study concludes: “Because there are no risk factors in using the X/GSE combination therapy, and Xlear nasal spray is over the counter available without a prescription, and Xlear allows for comfortable long term mask-wearing, adoption of this preventive anti-viral therapy should be encouraged.”
The imaging research study component was performed at the BioCryo facility of Northwestern University’s NUANCE Center, which received support from the SHyNE Resource (NSF ECCS-2025633), the IIN, and Northwestern’s MRSEC program (NSF DMR-1720139). No industry conflicts of interest were disclosed.
PrecisionVaccinations publishes research-based news.